1. [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan]
- Author
-
A, Tolo-Diebkilé, G K, Koffi, C D, Nanho, D, Sawadogo, B, Kouakou, L, Siransi-Bogui, R, Ayémou, and I, Sanogo
- Subjects
Male ,Maxillary Neoplasms ,Remission Induction ,Cytarabine ,Infant, Newborn ,Infant ,Burkitt Lymphoma ,Cote d'Ivoire ,Methotrexate ,Child, Preschool ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Facial Neoplasms ,Child ,Cyclophosphamide - Abstract
We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008. Their average age was 7.89 years, with a sex ratio of 2.71. The global response to the treatment was 92.3% with 57.7% of complete remission and 34.6% of incomplete remission. The morbidity related to treatment was essentially a haematological complication (84.6%) and hydroelectrolytic complication (84.6%). Evolution was made towards death in 30.8 and 15.4% were lost of view. The median monitoring was 18.2 months. Treatment response was linked to the therapeutic compliance (P0.001), and the delay of consultation (P = 0.01).
- Published
- 2010